to test the hypothesis that noradrenergic replacement may confer symptomatic benefit , a double-blind , placebo-controlled therapeutic trial with clonidine hydrochloride ( catapres ) , a centrally active noradrenergic receptor agonist , was undertaken in eight patients with the clinical diagnosis of alzheimer 's disease .
C0546860
clonidine hydrochloride
C0699881
catapres